A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps
Latest Information Update: 04 Jul 2025
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Acronyms Re-Open 3
- Sponsors OptiNose
Most Recent Events
- 27 Jun 2025 Planned initiation date (estimated date for recruitment of the first subject) changed from 18 Apr 2025 to 30 Jul 2025.
- 27 Jun 2025 Status changed from not yet recruiting to recruiting.
- 05 Mar 2025 New trial record